Utility of Monitoring Mycophenolic Acid in Solid Organ Transplant Patients

Total Page:16

File Type:pdf, Size:1020Kb

Utility of Monitoring Mycophenolic Acid in Solid Organ Transplant Patients Evidence Report/Technology Assessment Number 164 Utility of Monitoring Mycophenolic Acid in Solid Organ Transplant Patients Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-02-0020 Task Order Leader: Parminder Raina, Ph.D. Director, McMaster University Evidence-based Practice Center Co-Principal Investigators: Mark Oremus, Ph.D. Johannes Zeidler, Ph.D., D.A.B.C.C. Authors: Mark Oremus, Ph.D. Johannes Zeidler, Ph.D., D.A.B.C.C. Mary H.H. Ensom, Pharm.D., F.A.S.H.P., F.C.C.P., F.C.S.H.P. Mina Matsuda-Abedini, M.D.C.M., F.R.C.P.C. Cynthia Balion, Ph.D., F.C.A.C.B. Lynda Booker, B.A. Carolyn Archer, M.Sc. Parminder Raina, Ph.D. AHRQ Publication No. 08-E006 February 2008 This report is based on research conducted by the McMaster University Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0020). The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment. This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. This document is in the public domain and may used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders. Suggested Citation: Oremus M, Zeidler J, Ensom MHH, Matsuda-Abedini M, Balion C, Booker L, Archer C, Raina P. Utility of Monitoring Mycophenolic Acid in Solid Organ Transplant Patients. Evidence Report/Technology Assessment No. 164. (Prepared by the McMaster University Evidence-based Practice Center, under Contract No. 290-02-0020.) AHRQ Publication No.08-E006. Rockville, MD: Agency for Healthcare Research and Quality. February 2008. Financial Disclosure Statement: Dr. Matsuda-Abedini is the principal investigator for a research project with operational costs funded by Novartis. No other authors of this report have any financial or business interest in this field. ii Preface The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-Based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions and new health care technologies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments. To bring the broadest range of experts into the development of evidence reports and health technology assessments, AHRQ encourages the EPCs to form partnerships and enter into collaborations with other medical and research organizations. The EPCs work with these partner organizations to ensure that the evidence reports and technology assessments they produce will become building blocks for health care quality improvement projects throughout the Nation. The reports undergo peer review prior to their release. AHRQ expects that the EPC evidence reports and technology assessments will inform individual health plans, providers, and purchasers as well as the health care system as a whole by providing important information to help improve health care quality. We welcome comments on this evidence report. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by e-mail to [email protected]. Carolyn M. Clancy, M.D. Jean Slutsky, P.A., M.S.P.H. Director Director, Center for Outcomes and Evidence Agency for Healthcare Research and Quality Agency for Healthcare Research and Quality Beth A. Collins Sharp, PhD., R.N. Ernestine Murray, B.S.N., R.N., M.A.S. Director, EPC Program Task Order Officer, EPC Program Agency for Healthcare Research and Quality Agency for Healthcare Research and Quality iii Acknowledgments We thank the representatives of our partner organization, the American Association for Clinical Chemistry, Dr. Susan Maynard and Dr. Robert Christenson. We are grateful to members of the technical expert panel who were instrumental in developing the questions and defining the scope of this review: Dr. Klemens Budde, Dr. Guido Filler, Dr. Atholl Johnston, Dr. Les Shaw, and Dr. Maria Shipkova. Our thanks go to librarian Maureen Rice for her thorough management of the search terms and methodology. We would like to thank the following people who helped with the data abstraction for this review: Connie Freeborn, Rob Stevens, Carolina Ruiz Culebro, Alok Gupta, and Paula Robinson. Our editorial staff, Cecile Royer, Roxanne Cheeseman, and Sarah Smith, have provided invaluable input into this document. iv Structured Abstract Objectives: To investigate whether monitoring concentrations of mycophenolic acid (MPA) in the serum or plasma of persons who receive a solid organ transplant will result in a lower incidence of transplant rejections and adverse events versus no monitoring of MPA. To investigate whether the incidence of rejection or adverse events differs according to MPA dose or frequency, type of MPA, the form of MPA monitored, the method of MPA monitoring, or sample characteristics. To assess whether monitoring is cost-effective versus no monitoring. Data Sources: The following databases were searched from their dates of inception (in brackets) until October 2007: MEDLINE® (1966); BIOSIS® Previews (1976); EMBASE® (1980); Cochrane Database of Systematic Reviews® (1995); and Cochrane Central Register of Controlled Trials® (1995). Review Methods: Studies identified from the data sources went through two levels of screening (i.e., title and abstract, full text) and the ones that passed were abstracted. Criteria for abstraction included publication in the English language, study design (i.e., randomized controlled trial [RCT], observational study with comparison group, case series), and patient receipt of allograft solid organ transplant. Additionally, any form of MPA had to be measured at least once in the plasma or serum using any method of measurement (e.g., AUC0-12, C0). Furthermore, these measures had to be linked to a health outcome (e.g., transplant rejection). Certain biomarkers (e.g., serum creatinine, glomular filtration rate) and all adverse events were also considered health outcomes. Results: The published evidence on MPA monitoring is inconclusive. Direct, head-to-head comparison of monitoring versus no monitoring is limited to one RCT in adult, kidney transplant patients. Inferences about monitoring can be made from some observational studies, although the evidence is equivocal for MPA dose and dose frequency, nonexistent for type of MPA, inconclusive for form of MPA monitored or method of monitoring, and nonexistent for cost- effectiveness. Some studies suggest gender and concomitant use of calcineurin inhibitors will affect pharmacokinetic parameters, but the impact of these findings has not been assessed in relation to monitoring versus no monitoring. Conclusion: The state of knowledge about therapeutic drug monitoring of MPA in solid organ transplants is still in its infancy. Until there is more evidence on the utility of routine MPA monitoring in solid organ transplant recipients, patients, clinicians, and other stakeholders (e.g., public and private insurers) will have to decide on a case by case basis whether the possible but uncertain benefits are worth the extra time and expense of monitoring. v Contents Executive Summary........................................................................................................................... 1 Evidence Report............................................................................................................................... 9 Chapter 1. Introduction .................................................................................................................... 11 Mycophenolic Acid ...................................................................................................................... 11 Solid Organ Transplant................................................................................................................. 12 Mycophenolic Acid: Use in Solid Organ Transplants.................................................................. 12 Therapeutic Drug Monitoring of Mycophenolic Acid ................................................................. 14 Scope and Purpose of the Evidence Report.................................................................................. 15 Chapter 2. Methods.........................................................................................................................
Recommended publications
  • Us 8530498 B1 3
    USOO853 0498B1 (12) UnitedO States Patent (10) Patent No.: US 8,530,498 B1 Zeldis (45) Date of Patent: *Sep. 10, 2013 (54) METHODS FORTREATING MULTIPLE 5,639,476 A 6/1997 OShlack et al. MYELOMAWITH 5,674,533 A 10, 1997 Santus et al. 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL- 395 A 22 N. 2-YL)PIPERIDINE-2,6-DIONE 5,731,325 A 3/1998 Andrulis, Jr. et al. 5,733,566 A 3, 1998 Lewis (71) Applicant: Celgene Corporation, Summit, NJ (US) 5,798.368 A 8, 1998 Muller et al. 5,874.448 A 2f1999 Muller et al. (72) Inventor: Jerome B. Zeldis, Princeton, NJ (US) 5,877,200 A 3, 1999 Muller 5,929,117 A 7/1999 Muller et al. 5,955,476 A 9, 1999 Muller et al. (73) Assignee: Celgene Corporation, Summit, NJ (US) 6,020,358 A 2/2000 Muller et al. - 6,071,948 A 6/2000 D'Amato (*) Notice: Subject to any disclaimer, the term of this 6,114,355 A 9, 2000 D'Amato patent is extended or adjusted under 35 SS f 1939. All et al. U.S.C. 154(b) by 0 days. 6,235,756 B1 5/2001 D'Amatoreen et al. This patent is Subject to a terminal dis- 6,281.230 B1 8/2001 Muller et al. claimer 6,316,471 B1 1 1/2001 Muller et al. 6,326,388 B1 12/2001 Man et al. 6,335,349 B1 1/2002 Muller et al. (21) Appl. No.: 13/858,708 6,380.239 B1 4/2002 Muller et al.
    [Show full text]
  • Multinational Evaluation of Mycophenolic Acid, Tacrolimus
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE providedORIGINAL by University of QueenslandPAPER eSpace ISSN 1425-9524 © Ann Transplant, 2016; 21: 1-11 DOI: 10.12659/AOT.895664 Received: 2015.08.15 Accepted: 2015.09.01 Multinational Evaluation of Mycophenolic Published: 2016.01.05 Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization Authors’ Contribution: ABCDEF Kyle M. Gardiner School of Pharmacy, University of Queensland, Brisbane, QLD, Australia Study Design A ACDEF Susan E. Tett Data Collection B Statistical Analysis C ACDEF Christine E. Staatz Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G Corresponding Author: Christine E. Staatz, e-mail: [email protected] Source of support: Departmental funding only Background: Increasing immunosuppressant utilization and expenditure is a worldwide challenge as more people success- fully live with transplanted organs. Our aims were to characterize utilization of mycophenolate, tacrolimus, cy- closporin, sirolimus, and everolimus in Australian transplant recipients from 2007 to 2013; to identify specific patterns of usage; and to compare Australian utilization with Norwegian, Danish, Swedish, and the Netherlands use. Material/Methods: Australian utilization and expenditure data were captured through national Pharmaceutical Benefits Scheme and Highly Specialized Drug administrative databases. Norwegian, Danish, Swedish, and the Netherlands uti- lization were retrieved from their healthcare databases. Utilization was compared as defined daily dose per 1000 population per day (DDD/1000 population/day). Data on kidney transplant recipients, the predominant patient group prescribed these medicines, were obtained from international transplant registries. Results: From 2007–2013 Australian utilization of mycophenolic acid, tacrolimus and everolimus increased 2.7-fold, 2.2- fold, and 2.3-fold, respectively.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • WHO Drug Information Vol 22, No
    WHO Drug Information Vol 22, No. 1, 2008 World Health Organization WHO Drug Information Contents Challenges in Biotherapeutics Miglustat: withdrawal by manufacturer 21 Regulatory pathways for biosimilar Voluntary withdrawal of clobutinol cough products 3 syrup 22 Pharmacovigilance Focus Current Topics WHO Programme for International Drug Proposed harmonized requirements: Monitoring: annual meeting 6 licensing vaccines in the Americas 23 Sixteen types of counterfeit artesunate Safety and Efficacy Issues circulating in South-east Asia 24 Eastern Mediterranean Ministers tackle Recall of heparin products extended 10 high medicines prices 24 Contaminated heparin products recalled 10 DacartTM development terminated and LapdapTM recalled 11 ATC/DDD Classification Varenicline and suicide attempts 11 ATC/DDD Classification (temporary) 26 Norelgestromin-ethynil estradiol: infarction ATC/DDD Classification (final) 28 and thromboembolism 12 Emerging cardiovascular concerns with Consultation Document rosiglitazone 12 Disclosure of transdermal patches 13 International Pharmacopoeia Statement on safety of HPV vaccine 13 Cycloserine 30 IVIG: myocardial infarction, stroke and Cycloserine capsules 33 thrombosis 14 Erythropoietins: lower haemoglobin levels 15 Recent Publications, Erythropoietin-stimulating agents 15 Pregabalin: hypersensitivity reactions 16 Information and Events Cefepime: increased mortality? 16 Assessing the quality of herbal medicines: Mycophenolic acid: pregnancy loss and contaminants and residues 36 congenital malformation 17 Launch
    [Show full text]
  • Patient Focused Disease State and Assistance Programs
    Patient Focused Disease State and Assistance Programs Medication Medication Toll-free Brand (Generic) Website number Additional Resources Allergy/Asthma Xolair (omalizumab) xolair.com 1-866-4-XOLAIR lung.org Cardiovascular Pradaxa (dabigatran) pradaxa.com 877-481-5332 heart.org Praluent (alirocumab) praluent.com 844-PRALUENT thefhfoundation.org Repatha (evolocumab) repatha.com 844-REPATHA Tikosyn (dofetilide) tikosyn.com 800-879-3477 Crohn’s Disease Cimzia (certolizumab pegol) cimzia.com 866-4-CIMZIA crohnsandcolitis.com Humira (adalimumab) humira.com 800-4-HUMIRA crohnsforum.com Stelara (ustekinumab) stelarainfo.com 877-STELARA Dermatology Cosentyx (secukinumab) cosentyx.com 844-COSENTYX psoriasis.org Dupixent (dupilumab) dupixent.com 844-DUPIXENT nationaleczema.org Enbrel (etanercept) enbrel.com 888-4-ENBREL Humira (adalimumab) humira.com 800-4-HUMIRA Otezla (apremilast) otezla.com 844-4-OTEZLA Stelara (ustekinumab) stelarainfo.com 877-STELARA Taltz (ixekizumab) taltz.com 800-545-5979 Hematology Aranesp (darbepoetin alfa) aranesp.com 805-447-1000 chemocare.com Granix (filgrastim) granixrx.com 888-4-TEVARX hematology.org Jadenu (deferasirox) jadenu.com 888-282-7630 Neulasta (pegfilgrastim) neulasta.com 800-77-AMGEN Neupogen (filgrastim) neupogen.com 800-77-AMGEN Nivestym (filgrastim) nivestym.com 800-879-3477 Zarxio (filgrastim) zarxio.com 800-525-8747 Zytiga (abiraterone) zytiga.com 800-JANSSEN Hepatitis B Baraclude (entecavir) baraclude.com 800-321-1335 cdc.gov Viread (tenofovir disoproxil viread.com 800-GILEAD-5 hepb.org fumarate)
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0058872 A1 Crew Et Al
    US 2016.0058872A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0058872 A1 Crew et al. (43) Pub. Date: Mar. 3, 2016 (54) IMIDE-BASED MODULATORS OF A613 L/426 (2006.01) PROTEOLYSIS AND ASSOCATED METHODS A 6LX3 L/505 (2006.01) OF USE A613 L/454 (2006.01) A613 L/55 (2006.01) (71) Applicant: Arvinas, Inc., New Haven, CT (US) C07D40 L/4 (2006.01) A6II 45/06 (2006.01) (72) Inventors: Andrew P. Crew, Guilford, CT (US); (52) U.S. Cl. Craig Crews, New Haven, CT (US), CPC ............ A61K 47/481 (2013.01); C07D401/14 Hanging Dong, Madison, CT (US); Jing (2013.01); C07D 495/14 (2013.01); C07D Wang, Milford, CT (US); Yimin Qian, 417/14 (2013.01); A61K 45/06 (2013.01); Plainsboro, NJ (US); Kam Siu Milford, A6 IK3I/505 (2013.01); A61 K3I/454 CT (US); Meizhong Jin, East Northport, (2013.01); A61 K3I/551 (2013.01); A61 K NY (US) 3 1/426 (2013.01) (21) Appl. No.: 14/792,414 (57) ABSTRACT (22) Filed: Jul. 6, 2015 The description relates to imide-based compounds, including Related U.S. Application Data bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially (63) Continuation-in-part of application No. 14/686.640, inhibitors of a variety of polypeptides and other proteins filed on Apr. 14, 2015. which are degraded and/or otherwise inhibited by bifunc (60) Provisional application No. 61/979,351, filed on Apr. tional compounds according to the present invention. In par 14, 2014, provisional application No.
    [Show full text]
  • Hpra Drug Safety 66Th Newsletter Edition
    FEBRUARY 2015 HPRA DRUG SAFETY 66TH NEWSLETTER EDITION 3 Mycophenolate mofetil (CellCept) and 4 Direct Healthcare Professional In this Edition Mycophenolic acid (Myfortic) - New warnings Communications published on about the risks of hypogammaglobulinaemia the HPRA website since the last 1 Eligard (leuprorelin acetate depot injection) and bronchiectasis Drug Safety Newsletter - Risk of lack of efficacy due to incorrect reconstitution and administration process 4 Tecfidera (dimethyl fumarate) - Progressive Multifocal Leukoencephalopathy (PML) has 2 Beta interferons – Risk of thrombotic occurred in a patient with severe microangiopathy and nephrotic syndrome and prolonged lymphopenia Eligard (leuprorelin acetate depot injection) - Risk of lack of efficacy due to incorrect reconstitution and administration process Following identification of a signal and safe treatment of patients with It is available in six-monthly (45mg), of administration errors with Eligard prostate cancer. Lack of efficacy may three-monthly (22.5mg) and one- and concerns that such errors may occur due to incorrect reconstitution monthly (7.5mg) formulations. In impact on clinical efficacy, this issue of Eligard. the majority of patients, androgen was reviewed at EU level by the deprivation therapy (ADT) with Eligard Eligard is indicated for the treatment Pharmacovigilance Risk Assessment results in testosterone levels below the of hormone dependent advanced Committee (PRAC). A cumulative standard castration threshold (<50ng/ prostate cancer and for the treatment review of reported global cases dL; <1.7 nmol/L); and in most cases, of high risk localised and locally identified errors related to storage, patients reach testosterone levels advanced hormone dependent preparation and reconstitution of below <20ng/dL. prostate cancer in combination Eligard.
    [Show full text]
  • Forty-Sixth Annual MALTO Medicinal Chemistry & Pharmacognosy
    Forty-Sixth Annual MALTO Medicinal Chemistry & Pharmacognosy Meeting-in-Miniature May 20th – 22nd, 2019 Hosted by The Department of Pharmaceutical Sciences College of Pharmacy University of Tennessee Health Science Center, Memphis, TN A A O O M L M L T T 1 | Page 2019 MALTO Meeting At the University of Tennessee Health Science Center College of Pharmacy Table of Contents Page 2019 MALTO Contributors and Sponsors……………..………….……....4 2019 MALTO Executive Officers……………..……………..…………..…4 MALTO Board of Directors………………………………………..………5 MALTO 2019 Organizing Committee……………………………………..5 General Program…………………………………………………….……6-7 MALTO – A Brief History………………………………………………..8-9 A. Nelson Voldeng Memorial Lecture………………………...…….....10-11 Dr. Jeff Aubé, Fred Eshelman Distinguished Professor of Chemistry, The University of North Carolina Eshelman School of Pharmacy Biographical Information………………………………………..….11 Abstract………………………………………………………………12 History of The Robert A. Magarian Outstanding Podium Presentation Award ………………………..……………………………….…………13-15 History of The Thomas L. Lemke Outstanding Poster Presentation Award…………………………………………………………..… …….16-17 History of The Ronald F. Borne Outstanding Poster Presentation Award……………………………………………………………………18-19 Meeting Schedule for Monday, May 20th, 2019…………………….….…20 2 | Page Meeting Schedule for Tuesday, May 21st, 2019………………………20-26 Meeting Schedule for Wednesday, May 22nd, 2019…………………..27-28 Podium Presentation Abstracts………..……………………...………29-52 Poster Presentation Abstracts …………………..……….……………53-70 MALTO Primary Contacts………………………………………...….71-73
    [Show full text]
  • Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
    Journal of Clinical Medicine Review Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules Christine Verdon 1,2, Talat Bessissow 1 and Peter L. Lakatos 1,3,* 1 Division of Gastroenterology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada; [email protected] (C.V.); [email protected] (T.B.) 2 Department of Gastroenterology, Campbelltown Hospital, Sydney, NSW 2560, Australia 3 1st Department of Medicine, Semmelweis University, Budapest H1083, Hungary * Correspondence: [email protected]; Tel.: +514-934-1934 (ext. 45567) Received: 14 November 2019; Accepted: 6 December 2019; Published: 8 December 2019 Abstract: Acute severe ulcerative colitis (ASUC) is a medical emergency which occurs in about 20%–30% of patients with ulcerative colitis during their lifetime, and does carry a mortality risk of 1%. The management of inflammatory bowel diseases has evolved with changes in objective patient monitoring, as well as the availability of new treatment options with the development of new biological and small molecules; however, data is limited regarding their use in the context of ASUC. This review aims to discuss the emerging data regarding biologicals and small molecules therapies in the context of ASUC. Keywords: acute severe ulcerative colitis; infliximab; cyclosporine; tacrolimus; corticosteroids; surgical management 1. Introduction Acute severe ulcerative colitis (ASUC) is a life-threatening medical emergency which carries a 1% mortality rate [1]. Patients diagnosed with ulcerative colitis (UC) have a lifetime risk of 20%–30% of developing an acute flare of their disease requiring hospitalization [2]. Corticosteroids remain the mainstay of initial therapy but 30%–40% of patients who fail to respond will require second-line salvage treatment with mainly infliximab (IFX) or cyclosporine (CsA) [3,4].
    [Show full text]
  • Thesis Outline
    PHARMACOKINETICS, LIMITED SAMPLING STRATEGIES, AND PHARMACOGENETICS OF MYCOPHENOLIC ACID IN THORACIC TRANSPLANT RECIPIENTS by LILLIAN S.L. TING M.Sc., The University of British Columbia, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in The Faculty of Graduate Studies (Pharmaceutical Sciences) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) March, 2009. © Lillian S.L. Ting, 2009 ABSTRACT Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil, is an immunosuppressive agent known to exhibit wide inter-patient pharmacokinetic variability. The metabolism and transport of MPA and the phenolic (MPAG) and acyl (AcMPAG) glucuronides are mediated by UDP-glucuronosyltransferases (UGTs) and multidrug resistance-associated protein 2 (MRP2/ABCC2), respectively. Increasing evidence supports monitoring MPA area-under-the-concentration-time-curve; however, it is impractical and costly to implement. The objectives of this clinical study were to characterize MPA pharmacokinetics, develop MPA limited sampling strategies for estimating MPA exposure, and assess contribution of UGT and ABCC2 genetics to MPA pharmacokinetics and clinical outcomes in thoracic transplant recipients. Seventy thoracic (36 lung, 34 heart) transplant recipients were recruited. Eleven blood samples were obtained over a 12-hour dosing period at steady state. Plasma concentrations of MPA, MPAG, AcMPAG, and free MPA were measured by a high performance liquid chromatography-ultraviolet detection method, and conventional dose- normalized pharmacokinetic parameters were determined via non-compartmental methods. Limited sampling strategies were developed in 64 subjects by stepwise multiple regression analysis using the index group data, and tested in the validation group to determine bias and precision. Genetic polymorphisms in UGT and ABCC2 were determined by sequencing and their contributions to pharmacokinetic variability were investigated in 68 thoracic transplant recipients using multivariate analysis.
    [Show full text]
  • Mycophenolic Acid) Delayed-Release Tablets, for Oral Use System Disease
    HIGHLIGHTS OF PRESCRIBING INFORMATION Blood Dyscrasias including Pure Red Cell Aplasia (PRCA): Monitor for These highlights do not include all the information needed to use neutropenia or anemia; consider treatment interruption or dose reduction. MYFORTIC safely and effectively. See full prescribing information for (5.7) MYFORTIC. Serious GI Tract Complications (gastrointestinal bleeding, perforations and ulcers): Administer with caution to patients with active digestive MYFORTIC® (mycophenolic acid) delayed-release tablets, for oral use system disease. (5.8) Initial U.S. Approval: 2004 Immunizations: Avoid live vaccines. (5.9) WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES, AND Patients with Hereditary Deficiency of Hypoxanthine-guanine SERIOUS INFECTIONS Phosphoribosyl-transferase (HGPRT): May cause exacerbation of disease symptoms; avoid use. (5.10) See full prescribing information for complete boxed warning ------------------------------ADVERSE REACTIONS------------------------------- Use during pregnancy is associated with increased risks of pregnancy loss and congenital malformations. Females of reproductive potential Most common adverse reactions (≥20%): anemia, leukopenia, constipation, must be counseled regarding pregnancy prevention and planning. nausea, diarrhea, vomiting, dyspepsia, urinary tract infection, CMV infection, (5.1, 8.1, 8.6) insomnia, and postoperative pain. (6.2) Increased risk of development of lymphoma and other malignancies, To report SUSPECTED ADVERSE REACTIONS, contact Novartis particularly of the skin,
    [Show full text]
  • Immunosuppressive Therapy DR
    OCTOBER 2017 Immunosuppressive Therapy DR. ANDREW MACKIN BVSc BVMS MVS DVSc FANZCVSc DipACVIM Professor of Small Animal Internal Medicine Mississippi State University College of Veterinary Medicine, Starkville, MS A number of established immunosuppressive agents have been used in small animal medicine for many decades. Some have justifiably fallen out of favor whereas, for others, new and promising uses have been described in the recent veterinary literature. Established “old favorites” have included cyclophosphamide, chlorambucil, azathioprine, danazol and vincristine, although cyclophosphamide and danazol are rarely used as immunosuppressive agents these days. Several potent immunosuppressive drugs developed over the past few decades in human medicine have recently made the leap to our small animal patients, and our use of drugs such as cyclosporine, leflunomide and mycophenolate is growing. Cyclophosphamide Cyclophosphamide, a cell-cycle nonspecific nitrogen mustard derivative alkylating agent, was one of the first major chemotherapeutic agents approved by the FDA over 50 years ago, and has since become very well-established in human medicine as both an antineoplastic drug and as an immunosuppressive agent. Within a few years of FDA approval in the late 1950s, the use of cyclophosphamide for the prevention of transplant rejection in experimental models and for the treatment of both neoplasia and immune-mediated diseases was described in both dogs and cats. Cyclophosphamide has persisted to this day as one of the core drugs used in many small animal cancer chemotherapeutic protocols. In contrast, after many years as one of the most commonly immunosuppressive drugs utilized to treat immune-mediated diseases in cats and dogs, the use of cyclophosphamide as an immunosuppressive agent in small animal patients has in the past two decades essentially faded away.
    [Show full text]